Sector News

Former Valeant CFO Schiller to step in for hospitalized CEO Pearson

January 6, 2016
Life sciences

Last week, Valeant CEO J. Michael Pearson, in the hospital with severe pneumonia, took a medical leave of absence. And now, the company is putting a new chief in his place.

Former Valeant CFO and board member Howard Schiller will step in for Pearson on an interim basis, effective immediately, Valeant said Wednesday morning. Robert Ingram, the company’s lead independent director, will serve as interim chairman.

“Howard’s performance as Valeant’s CFO, as well as his deep understanding of Valeant’s operations, are excellent and we are grateful that he has agreed to take on this role. The board will continue to work closely with Howard and the other members of the senior management team to implement Valeant’s strategy successfully in Mike’s absence,” Ingram said in a statement, noting that the timing of Pearson’s recovery and return “remains uncertain.”

Schiller, who served as Valeant’s CFO from December 2011 through June 2015, will step in for the three-man Office of the Chief Executive Officer–comprising General Counsel Robert Chai-Onn, Company Group Chairman Ari Kellen and current CFO Robert Rosiello–that’s been running the show in Pearson’s stead since Dec. 28.

The move marks one of many recent changes for the Quebec-based drugmaker, which has floundered lately amid political scrutiny over its pricing practices and allegations that it used its relationship with specialty pharmacy Philidor to inflate its top line. To fill the void after cutting ties with Philidor, the company announced a pricing and distribution deal with Walgreens last month–as well as plans to scrap “virtually all” of its planned price hikes for this year.

But despite the beating the company’s stock has taken throughout the course of the controversy, Valeant’s board has continued to back Pearson, who has remade the company into a skincare and eye-care-focused M&A machine since taking the helm in 2008.

“Mike remains focused on running the business and has been meeting with physicians, partners, and other stakeholders,” company spokeswoman Laurie Little told Bloomberg by email in November. “Despite recent market volatility that has impacted our stock price, Valeant’s core business remains strong and is well positioned for growth.”

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach